Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The discovery and development of structurally distinct lysine methyltransferase G9a inhibitors have been the subject of intense research in epigenetics. Structure-based optimization was conducted, starting with the previously reported seed compound 7a and lead to the identification of a highly potent G9a inhibitor, compound 7i (IC = 0.024 μM). X-ray crystallography for the ligand-protein interaction and kinetics study, along with surface plasmon resonance (SPR) analysis, revealed that compound 7i interacts with G9a in a unique binding mode. In addition, compound 7i caused attenuation of cellular H3K9me2 levels and induction of γ-globin mRNA expression in HUDEP-2 cells in a dose-dependent manner.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2024.129856 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting G9a decreases escalated alcohol drinking in male mice in a model of combined stress and chronic alcohol exposure.
Alcohol Clin Exp Res (Hoboken)
September 2025
Department of Neuroscience, Medical University of South Carolina, Charleston, South Carolina, USA.
Background: Alcohol use disorder (AUD) is a pervasive problem in society afflicting millions of people worldwide. One reason for the prevalence of AUD is that heavy alcohol drinking can produce alcohol dependence. In addition, alcohol dependence dysregulates the body's stress systems to increase alcohol drinking.
View Article and Find Full Text PDFDiscovery of 2-tetrahydroisoquinoline substituted quinazoline derivatives as lysine methyltransferase G9a inhibitors with in vivo antitumor efficacy.
Eur J Med Chem
September 2025
Shanghai Frontiers Science Center of Drug Target Identification and Delivery, National Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China; State Key Laboratory of Innovative Immunotherapy, Central Research Institute,
Overexpression of protein lysine methyltransferase G9a, which catalyzes mono- and di-methylation of histone H3K9 and non-histone proteins, is closely associated with poor prognosis and metastasis of various cancers. Here, we designed and synthesized a series of novel G9a inhibitors bearing 2-tetrahydroisoquinoline substituted quinazoline scaffold. Among them, compound 31 with 2-dioxole fused tetrahydroisoquinoline exhibited the most potent inhibitory effects against G9a with an IC value of 0.
View Article and Find Full Text PDFA Novel PROTAC G9a/GLP Degrader that Inhibits, Similar to G9a siRNA, the Migration of MCF-7 Breast-Cancer Cells without Affecting Proliferation.
J Med Chem
August 2025
SANKEN, The University of Osaka, 8-1 Mihogaoka, Ibaraki, Osaka 567-0047, JAPAN.
G9a and G9a-like protein (GLP) are histone methyltransferases that regulate epigenetics by adding methyl groups to histone H3, thereby controlling gene expression. G9a/GLP dysregulation and overexpression have been reported to cause cancer proliferation, progression, and metastasis. So far, quinazoline-based inhibitors and degraders have been frequently used as chemical tools to elucidate the role of G9a/GLP.
View Article and Find Full Text PDFInhibition of histone methyltransferase G9a promotes the osteogenic potential of bone-derived stem cells in diabetic-osteoporosis by regulating the LINC00657/miR-204-5p/IGFBP5 pathway.
Front Endocrinol (Lausanne)
August 2025
Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Background: Bone mesenchymal stem cells (BMSCs) from patients with diabetes often exhibit reduced osteogenic potential. This study aimed to investigate the mechanism of action of G9a, known as euchromatic histone lysine methyltransferase 2 (EHMT2), identify its key responsive long non-coding RNA in diabetic osteoporosis (DOP), and evaluate the effectiveness of the G9a inhibitor (UNC0638).
Methods: The expression level of G9a in bone-derived MSCs (BMSCs) from osteoporosis patients with or without T2DM (T2DM-BMSCs, CON-BMSCs) was detected, and osteogenic differentiation was evaluated by osteogenic genes, ALP activity and calcification level.
Increased autophagy activity suppresses hyperglycemia-related colorectal cancer tumorigenesis both and .
Am J Cancer Res
July 2025
Master of Science Program in Tropical Medicine, College of Medicine, Kaohsiung Medical University Kaohsiung, Taiwan.
Hyperglycemia contributes to recurrence, poor survival, and drug resistance in colorectal cancer (CRC) patients. Overexpression of G9a (euchromatic histone-lysine N-methyltransferase 2, EHMT2), together with decreased autophagy activity, has been implicated in promoting CRC tumorigenesis and chemoresistance. Here, we demonstrate that high glucose (25 mM) enhances proliferation, focus formation, and migration of CRC cells, while concurrently suppressing autophagy activity.
View Article and Find Full Text PDF